Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879352 | 0.77 | TSHR (0.32) | TSHR | |
| SCHEMBL15482484 | 0.75 | TSHR (0.42) | MAPTCACNA1BAPBA1TSHRCYP3A4 | |
| SCHEMBL711893 | 0.75 | NPSR1 (0.44) | MAPTTSHRPKM | |
| SCHEMBL2079724 | 0.75 | NPSR1 (0.44) | MAPTTSHRPKM | |
| SCHEMBL9491837 | 0.74 | MAPT (0.41) | MAPTCACNA1BAPBA1TSHRCYP3A4 | |
| SCHEMBL9491841 | 0.74 | MAPT (0.41) | MAPTCACNA1BAPBA1TSHRCYP3A4 | |
| SCHEMBL11873857 | 0.74 | MAPT (0.41) | MAPTCACNA1BAPBA1TSHRCYP3A4 | |
| SCHEMBL6050174 | 0.73 | MAPT (0.46) | MAPTCACNA1BAPBA1TSHRCYP3A4 | |
| SCHEMBL15482672 | 0.73 | TSHR (0.47) | MAPTCACNA1BAPBA1TSHRCYP3A4 | |
| SCHEMBL15482576 | 0.71 | TDP1 (0.42) | MAPTCACNA1BAPBA1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984742-B2 | Method for preparing polyprenyl compounds | NIKKEN CHEMICALS CO., LTD. (JP) | 2006-01-10 | — | — | US | disclosed |
| US-20040242690-A1 | Method for preparing polyprenyl compounds | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242690-A1 | Method for preparing polyprenyl compounds | CYP11B2, CBR1, CUL2 | MAPT 2566/4885CACNA1B 4189/4885APBA1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.